Published in Virchows Arch on August 17, 2016
EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer (EUCROSS) | NCT02183870
ROS1 fusions rarely overlap with other oncogenic drivers in non-small cell lung cancer. J Thorac Oncol (2017) 0.77
ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer. Lung India (2017) 0.77
Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. Oncotarget (2017) 0.75
Recent Advances in Targeting ROS1 in Lung Cancer. J Thorac Oncol (2017) 0.75
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol (2017) 0.75
Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Arch (2017) 0.75
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
RET, ROS1 and ALK fusions in lung cancer. Nat Med (2012) 6.76
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA (2014) 6.32
Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res (2012) 3.80
Cellular sequences related to three new onc genes of avian sarcoma virus (fps, yes, and ros) and their expression in normal and transformed cells. J Virol (1982) 2.69
Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer (2003) 2.67
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res (2012) 2.66
Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res (2012) 2.53
Anchored multiplex PCR for targeted next-generation sequencing. Nat Med (2014) 2.25
Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One (2011) 2.17
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin Cancer Res (2015) 2.12
Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. J Thorac Oncol (2015) 2.12
Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A (1987) 2.11
Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist (2013) 2.04
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol (2015) 1.95
Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res (2013) 1.94
The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta (2008) 1.77
Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res (2012) 1.56
ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol (2013) 1.52
RNA extraction from ten year old formalin-fixed paraffin-embedded breast cancer samples: a comparison of column purification and magnetic bead-based technologies. BMC Mol Biol (2007) 1.45
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch (2012) 1.34
Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis (2007) 1.34
Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc Natl Acad Sci U S A (2003) 1.33
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol (2013) 1.23
ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol (2013) 1.20
ROS1 fusions in Chinese patients with non-small-cell lung cancer. Ann Oncol (2013) 1.17
Formalin fixation at low temperature better preserves nucleic acid integrity. PLoS One (2011) 1.16
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol (2014) 1.16
Clinical Implications of Genomic Discoveries in Lung Cancer. N Engl J Med (2016) 1.13
The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res (2012) 1.10
ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology (2014) 1.10
Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol (2013) 1.09
On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer (2013) 1.09
A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn (2014) 1.06
A Screening Method for the ALK Fusion Gene in NSCLC. Front Oncol (2012) 1.04
Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis (2013) 1.03
Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Mod Pathol (2014) 1.02
Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch (2014) 1.00
Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. J Thorac Oncol (2013) 0.97
Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. PLoS One (2014) 0.95
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget (2015) 0.95
Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget (2015) 0.94
Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Lung Cancer (2014) 0.94
Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples. Transl Oncol (2014) 0.91
Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung. N Engl J Med (2011) 0.90
Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. Lung Cancer (2014) 0.89
ROS1 gene rearrangement and copy number gain in non-small cell lung cancer. Virchows Arch (2014) 0.89
Mouse model for ROS1-rearranged lung cancer. PLoS One (2013) 0.88
Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget (2015) 0.87
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget (2014) 0.87
Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR. PLoS One (2015) 0.84
Role of fluorescence in situ hybridization in lung cancer cytology. Acta Cytol (2012) 0.84
Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing. Lung Cancer (2014) 0.83
Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax (2015) 0.81
ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer (2014) 0.80
The pre-analytical phase in surgical pathology. Recent Results Cancer Res (2015) 0.80
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients. Diagn Cytopathol (2015) 0.80
Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance. Cancer Chemother Pharmacol (2016) 0.80
External quality control for immunocytochemistry on cytology samples: a review of UK NEQAS ICC (cytology module) results. Cytopathology (2011) 0.79
[Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation]. Zhonghua Bing Li Xue Za Zhi (2015) 0.79
The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients. PLoS One (2015) 0.78
Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay. J Thorac Oncol (2014) 0.78
Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol (2014) 0.78
Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report. Oncol Lett (2014) 0.78
[Detection of ROS1 gene rearrangement by FISH and analysis of its clinical features in non-small cell lung cancer patients]. Zhonghua Zhong Liu Za Zhi (2014) 0.77
Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. Onco Targets Ther (2015) 0.77
CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. Oncol Rep (2013) 0.77
The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization. PLoS One (2014) 0.76
Immunohistochemistry practices of cytopathology laboratories: a survey of participants in the College of American Pathologists Nongynecologic Cytopathology Education Program. Arch Pathol Lab Med (2014) 0.76
Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer. Lung (2016) 0.76
Erratum to: ROS1 gene rearrangement and copy number gain in non-small cell lung cancer. Virchows Arch (2015) 0.75
Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Mod Pathol (2014) 0.92
Polymorphisms of drug-metabolizing enzymes CYP1A1, GSTT and GSTP contribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population. Leuk Lymphoma (2008) 0.87
Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax (2015) 0.81
Glutathione S-transferase-pi protein expression in prostate cancer--not always a useful diagnostic tool. Histopathology (2015) 0.77
MED12 is recurrently mutated in Middle Eastern colorectal cancer. Gut (2017) 0.76
Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: Results from the ETOP Lungscape Project. J Thorac Oncol (2017) 0.75
Glycine decarboxylase and HIF-1α expression are negative prognostic factors in primary resected early-stage non-small cell lung cancer. Virchows Arch (2017) 0.75
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. Eur J Cancer (2017) 0.75
Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol (2017) 0.75
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol (2020) 0.75
Expanding the spectrum of germline variants in cancer. Hum Genet (2017) 0.75
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer (2015) 0.75